Market Overview:

Bronchiectasis is a chronic lung disease characterized by abnormal dilatation of the bronchi. It majorly develops as a result of frequent lower respiratory tract infections, asthma, tuberculosis and autoimmune disorders. The main symptoms include chronic cough, recurring infections and formation of excess mucus in the lungs. Bronchiectasis drugs include antibiotics, bronchodilators, expectorants and mucolytics which help in reducing symptoms and lung infections.

Market Dynamics:

The bronchiectasis drugs market is primarily driven by increasing prevalence of respiratory diseases such as chronic obstructive pulmonary disease and cystic fibrosis that can lead to bronchiectasis. According to the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD), over 65 million people suffer from moderate to severe COPD worldwide. Similarly, as per Cystic Fibrosis Foundation, around 30,000 people in the US are living with cystic fibrosis. Secondly, rising geriatric population is also fueling market growth as older people are more susceptible to developing bronchiectasis. Additionally, ongoing research and development activities for development of novel and targeted therapies are further propelling market expansion.

SWOT Analysis

Strength: The bronchiectasis drugs market has strong presence of key players with robust pipeline drugs. The ongoing research and development activities by market players to develop novel and effective drugs is also boosting the market growth. Growing cases of bronchiectasis worldwide is generating high demand for effective treatment options in the market.

Weakness: High costs associated with drug development and clinical trials can hamper the market growth. Moreover, lack of awareness about bronchiectasis in some parts of the world also restricts the market penetration.

Opportunity: Rising geriatric population worldwide prone to developing respiratory diseases acts as an opportunity. Moreover, favorable government support and initiatives to increase awareness regarding bronchiectasis treatment options will drive the market growth.

Threats: Patent expiry of blockbuster drugs and introduction of generic versions can negatively impact the market revenues of players. Stringent regulations for drug approval is another threat.

The global Bronchiectasis Drugs Market Demand is estimated to be valued at US$ 303.8 Mn in 2023 and is expected to exhibit a CAGR of 10 % over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Key Takeaways:

The global bronchiectasis drugs market is expected to witness high growth, exhibiting CAGR of 10% over the forecast period, due to increasing prevalence of bronchiectasis worldwide. As per the reports, around 106 to 260 cases per 100,000 population are reported globally each year.

Regional analysis – North America is expected to dominate the global bronchiectasis drugs market over the forecast period due to growing patients diagnosed with bronchiectasis, rising healthcare expenditure, and presence of key players in the region. Europe is also expected hold a significant market share owing to increasing research on novel therapeutics and rising geriatric population susceptible to respiratory diseases.

Key players operating in the bronchiectasis drugs market are GlaxoSmithKline plc, Novartis AG, Pfizer Inc., AstraZeneca plc, Boehringer Ingelheim International GmbH, Roche Holding AG, Teva Pharmaceutical Industries Ltd., Bayer AG, Sanofi S.A., Sunovion Pharmaceuticals Inc., Mylan N.V., Cipla Ltd., Grifols S.A., Insmed Incorporated, Arbor Pharmaceuticals LLC. These players are engaged in developing and commercializing novel drugs to expand their market share.

Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it